A Phase I/II open-label multicenter study of AT7519M alone and in combination with bortezomib in patients with previously treated multiple myeloma
ID Number 10-1658Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to evaluate the safety and effectiveness of a drug called AT7519M combined with bortezomib in patients with previously treated multiple myeloma (MM). AT7519M is an investigational drug which means that the drug is still being studied and that research doctors are trying to find out more about it. It also means that the FDA (Food and Drug Administration) has not approved AT7519M for any type of cancer, including your type. The study drug, AT7519M, works by blocking certain cellular processes that are involved in MM cell growth and multiplication. By inhibiting these cell processes, MM cells are unable to grow and multiply, thereby slowing cancer growth. Bortezomib is a drug which is approved by the FDA for use in multiple myeloma. Bortezomib is thought to slow down the production of many proteins (known as ‘proteasomes’) that cancer cells need to survive and multiply. It is believed that combining bortezomib with AT7519M may be more effective in slowing cancer growth than if either drug is used alone.
Recruiting Patients: Yes